The Role of EGFR Inhibitor Therapy as Post-Operative Treatment for Early Stage NSCLC: A Controversial Question (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Jared Weiss, medical oncologist from the Univ. of Pennsylvania, covers limited data and current clinical trials addressing potential role of EGFR inhibitors, and particularly Tarceva (erlotinib), as...